Compare PSTL & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSTL | MNPR |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.7M | 587.4M |
| IPO Year | 2018 | 2019 |
| Metric | PSTL | MNPR |
|---|---|---|
| Price | $23.16 | $110.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $20.19 | ★ $107.00 |
| AVG Volume (30 Days) | 252.1K | ★ 274.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.62% | N/A |
| EPS Growth | ★ 123.81 | 54.99 |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $95,823,000.00 | N/A |
| Revenue This Year | $18.01 | N/A |
| Revenue Next Year | $11.38 | N/A |
| P/E Ratio | $89.23 | ★ N/A |
| Revenue Growth | ★ 25.47 | N/A |
| 52 Week Low | $14.25 | $29.18 |
| 52 Week High | $25.22 | $124.82 |
| Indicator | PSTL | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.02 | 52.76 |
| Support Level | $22.12 | $102.88 |
| Resistance Level | $24.28 | $114.60 |
| Average True Range (ATR) | 0.69 | 6.69 |
| MACD | -0.04 | -1.43 |
| Stochastic Oscillator | 50.24 | 26.91 |
Postal Realty Trust Inc is an internally managed real estate investment trust. It is engaged in acquiring and managing properties mainly leased to the United States Postal Service, or the USPS, ranging from last-mile post offices to industrial facilities. The Trust's objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of its revenue is generated in the form of rental income.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.